middle.news

How Patrys’ New Injectable Antipsychotic Could Transform $2B Delirium Market

9:22am on Wednesday 26th of November, 2025 AEDT Healthcare
Read Story

How Patrys’ New Injectable Antipsychotic Could Transform $2B Delirium Market

9:22am on Wednesday 26th of November, 2025 AEDT
Key Points
  • Acquisition of Reliis adds injectable Quetiapine (RLS-2201) targeting delirium
  • Addresses a US$2 billion+ global market with no approved acute delirium treatments
  • Near-term clinical milestones include Phase 0 and Phase I trials planned
  • Deal includes issuing 110 million shares and 70 million performance rights
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about PAB
OPEN ARTICLE